Literature DB >> 9473229

In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody.

D MacGlashan1, J McKenzie-White, K Chichester, B S Bochner, F M Davis, J T Schroeder, L M Lichtenstein.   

Abstract

In vivo studies suggested the possibility of an IgE-dependent regulation of high-affinity (FcepsilonRI) IgE receptor expression on basophils. The current studies extend these observations to in vitro cultures of human basophils. Incubation of basophils for 3 to 4 weeks resulted in a slow dissociation of IgE antibody, during which time FcepsilonRI expression decreased, as measured by flow cytometry using the anti-FcepsilonRIalpha monoclonal antibody, 22E7, or by measuring FcRIalpha mass by Western blotting of whole-cell lysates. Culture of basophils with IgE resulted in upregulation of FcepsilonRIalpha expression by both flow cytometry and Western blotting of whole-cell lysates. Upregulation followed a linear time course during 2 weeks of culture. The relative increase in FcepsilonRIalpha density depended on the starting density; with starting densities of FcepsilonRIalpha of 10,000 to 170,000 per basophil, the upregulation varied 20- to 1.1-fold, respectively. Upregulation occurred in high-purity basophils, was not influenced by IgG at concentrations up to 1 mg/mL, and was inhibited by dimeric IgE. Heat-inactivated IgE was less effective and the monoclonal antibody CGP51901 that prevents IgE binding to FcepsilonRIalpha blocked the ability of IgE to induce upregulation. The dose-response curve for IgE-induced upregulation had an effective concentration50 of 230 ng/mL. Although the receptor through which IgE induces this upregulation is not yet known, several characteristics suggest that the upregulation is mediated by IgE interacting through FcepsilonRIalpha itself.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9473229

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  Mast cells. Receptors, secretagogues, and signaling.

Authors:  Bhavya B Sharma; John R Apgar; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

2.  Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice.

Authors:  Hans D Brightbill; Surinder Jeet; Zhonghua Lin; Donghong Yan; Meijuan Zhou; Martha Tan; Allen Nguyen; Sherry Yeh; Donnie Delarosa; Steven R Leong; Terence Wong; Yvonne Chen; Mark Ultsch; Elizabeth Luis; Sree Ranjani Ramani; Janet Jackman; Lino Gonzalez; Mark S Dennis; Anan Chuntharapai; Laura DeForge; Y Gloria Meng; Min Xu; Charles Eigenbrot; Wyne P Lee; Canio J Refino; Mercedesz Balazs; Lawren C Wu
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

Review 3.  Deciphering the structure and function of FcεRI/mast cell axis in the regulation of allergy and anaphylaxis: a functional genomics paradigm.

Authors:  Jayapal Manikandan; Narasimhan Kothandaraman; Manoor Prakash Hande; Peter Natesan Pushparaj
Journal:  Cell Mol Life Sci       Date:  2011-12-07       Impact factor: 9.261

Review 4.  IgE and FcepsilonRI regulation.

Authors:  Donald MacGlashan
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

Review 5.  Omalizumab: a monoclonal anti-IgE antibody.

Authors:  Paul P Belliveau
Journal:  MedGenMed       Date:  2005-01-27

6.  The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation.

Authors:  M Huber; C D Helgason; J E Damen; L Liu; R K Humphries; G Krystal
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

Review 7.  Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases.

Authors:  Oliver T Burton; Hans C Oettgen
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

Review 8.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

Review 9.  [Application of humanized Anti-IgE antibodies (omalizumab). A new principle in the treatment of allergic diseases in ENT medicine].

Authors:  O Pfaar; L Klimek
Journal:  HNO       Date:  2007-12       Impact factor: 1.284

10.  Coaggregation of FcepsilonRI with FcgammaRIIB Inhibits Degranulation but Not Induction of Bcl-2 Family Members A1 and Bim in Mast Cells.

Authors:  Maria Ekoff; Christine Möller; Zou Xiang; Gunnar Nilsson
Journal:  Allergy Asthma Clin Immunol       Date:  2006-09-15       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.